Synjardy Xr generic
Synjardy Xr is an anti-diabetic drug owned by Boehringer Ingelheim. It contains the active ingredients Empagliflozin and Metformin Hydrochloride. The drug was first authorized for market use on December 9, 2016, and holds a total of 14 patents, none of which have expired yet.
When will Synjardy Xr generic be available?
The generic version of Synjardy Xr can be expected to enter the market after December 11, 2034. This date is determined by the patent with the longest extent, which holds the patent title 'Pharmaceutical composition, methods for treating and uses thereof' and is due to expire on this date.
Synjardy Xr uses
Synjardy Xr is primarily used for treating type 2 diabetes mellitus in patients with different stages of renal impairment. By initiating the use of the Empagliflozin and Metformin HCl combination, the drug controls the patient's glycemic levels. It is particularly effective in treatment-naïve patients with inadequately controlled type 2 diabetes and reduces the risk of cardiovascular death in adult patients with diabetes and cardiovascular disease.
Synjardy Xr patent expiration
Synjardy Xr is protected by 14 patents, the last of which is set to expire on December 11, 2034. This patent, titled 'Pharmaceutical composition, methods for treating and uses thereof', holds the key to the release of Synjardy Xr generics. Below are the details of the patent: